151751-Najiba-Chargi

242 CHAPTER 13 Table 1. (Continued) Author and Date n Type of Cancer Measure low SMM Occurrence low SMM n (%) or Mean (SD) Location Analyzed Anti-Cancer Drug Measure of Toxicity Occurrence Toxicity n (%) Palmela et al. 2017 30 47 Stomach or gastroesophageal junction 2 11 (23%) CT-L3 A combination of 2–3: epirubicin, cisplatin, 5-FU, oxaliplatin, docetaxel, leucovorin, or capecitabine DLT a 21 (44.7%) Panje et al. 2019 31 61 Locally advanced esophageal 2 18 (29.5%) CT-L3 Docetaxel + cisplatin with/ without cetuximab ≥grade 3 toxicity 37 (60.7%) Parsons et al. 2012 16 48 Liver metastasis 1 20 (42.0%) CT-L3 HAI oxaliplatin + leucovorin + 5-FU + bevacizumab ≥grade 3 toxicity Not given Prado et al. 2009 6 55 Metastatic breastcancer 1 14 (25.5%) CT-L3 Capecitabine ≥grade 2 toxicity 15 (27.3%) Sawada et al. 2019 33 82 Hepatocellular 4 16 (19.5%) CT-L3 Sorafenib DLT a 27 (32.9%) Sealy et al. 2020 34 213 Head and neck cancer Continuous SMI L3: 51.62 (10.16) T4: 65.53 (12.60) CT-L3 or CT-T4 Cisplatin or carboplatin DLT a 61 (29.0%) Shachar et al. 2017a 35 40 Metastatic breast ≤41 cm 2 /m 2 23 (58%) CT-L3 Paclitaxel, docetaxel, or nab-paclitaxel combined with trastuzumab, pertuzumab, or bevacizumab DLT a 23 (58.0%) Shachar et al. 2017b 36 151 Early breast cancer Continuous SMI 44.72 (6.86) CT-L3 Adraimycin + cyclophosphamide ≥grade 3 toxicity 50 (33.1%) Srdic et al. 2016 37 100 Non-small cell lung cancer 1 47 (47%) CT-L3 Platinum based chemotherapy with gemcitabine, paclitaxel or etoposide ≥grade 2 toxicity during first cycle 57 (57.0%) Staley et al. 2019 38 134 Epithelial ovarian ≤41 cm 2 /m 2 73 (54.5%) CT-L3 Platinum and taxan-based chemotherapy Dose delay or reduction 51 (38.1%) 50 (37.3%) c Sugiyama et al. 2018 39 118 Metastatic gastric 1 105 (89.0%) CT-L3 FP with cisplatin or oxaliplatin ≥grade 3 toxicity Not given Tan et al. 2015 16 89 Esophago-gastric 1 44 (49.4%) CT-L3 Cisplatin + 5-FU or epirubicin + cisplatin + capecitabine DLT a 37 (41.6%) Ueno et al. 2020 40 82 Breast cancer 5 10 (12.2%) CT-L3 Epirubicin + cyclophosphamide ≥grade 3 laboratory toxicity 23 (28.0%) Wendrich et al. 2017 8 112 Squamous cell head and neck cancer ≤43.2 cm 2 /m 2 61 (54.5%) CT- C3 Cisplatin or carboplatin DLT a 34 (30.4%) 5-FU: 5-Fluorouracil; BMI: body mass index; CAP-B: capecitabine and bevacizumab; CAPOX: Capecitabine and oxaliplatin; CAPOX-B: Capecitabine, oxaliplatin, and bevacizumab; C3: cervical vertebrae 3; CT: computed tomography; FOLFOX: oxaliplatin, leucovorin, 5-fluorouracil; FP: fluoropyrimidine; HAI: hepatic arterial infusion; HIPEC: hyperthermic intraperitoneal chemotherapy; L3: Lumbar vertebrae 3; Low SMM: low skeletal muscle mass; MRI: magnetic resonance imaging; NS: not significant; SMI: skeletal muscle index (skeletal muscle area/height2); T4: thoracic vertebrae 4. a. DLT (dose-limiting toxicity): toxicity leading to dose reduction, treatment delay, or discontinuation b. Occurrence of DLT for CAPOX-B and CAP-B respectively c. Occurrence of dose delay and dose reduction respectively Definitions of low SMM 1. Prado et al. 2008 46 : <52.4 cm 2 /m 2 for men and <38.5 cm 2 /m 2 for women 2. Martin et al. 2013 47 : <43 cm 2 /m 2 for men if BMI ≤24.9 kg/m 2 or <53cm 2 /m2 for men if BMI >25kg/m 2 and <41 cm 2 /m 2 for women 48 3. 25th percentile < 44.8cm 2/ m 2 vs 75th percentile >63.2cm 2/ m 2 4. Fujiwara et al. 2015 48 : ≤36.2 cm 2 /m 2 for men and ≤29.6 cm 2 /m 2 for women 5.Caan et al. 2018 49 : <40 cm 2 /m 2